West Pharmaceutical Services

US · WST #752 by market cap Listed 1970

366.48 -6.16 -1.65%

Live - 5344 symbols - heartbeat 276s ago · 2026-10-08 07:35

Pre-market 366.60 +0.03%

After-hours 366.48 0.00%

Overnight 368.00 +0.41%

Market cap: 25.79B
P/E (TTM): 46.92
P/B: 8.63
EPS: 6.79
Div yield: 0.24%
52W pos: 88%

Reader sentiment Are you bullish or bearish on WST?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 17.16, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +6.25% YoY

Margins

Gross margin: 35.91%
Operating margin: 20.69%
Net margin: 16.06%

Key ratios & quality

Enterprise value: 25.23B
Altman Z-Score: 17.16

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	1.72B	1.84B	2.15B	2.83B	2.89B	2.95B	2.89B	3.07B
Gross profit	545.40M	605.70M	767.80M	1.18B	1.14B	1.13B	998.50M	1.10B
Selling & admin expenses	262.90M	272.70M	302.00M	362.80M	316.90M	353.40M	338.50M	393.60M
Research & development	40.30M	38.90M	46.90M	52.80M	58.50M	68.40M	69.10M	74.30M
Operating profit	242.20M	298.80M	418.90M	760.20M	760.80M	707.40M	590.90M	636.10M
Pretax profit	240.70M	291.80M	401.30M	748.90M	679.90M	698.00M	585.50M	600.90M
Tax	41.40M	59.00M	72.50M	107.20M	114.70M	122.30M	107.50M	121.60M
Net profit	206.90M	241.70M	346.20M	661.80M	585.90M	593.40M	492.70M	493.70M
Basic EPS	3	3	5	9	8	8	7	7
Diluted EPS	2.74	3.21	4.57	8.67	7.73	7.88	6.69	6.79

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	698.00M	766.50M	804.60M	805.00M	844.90M	872.30M
Gross profit	231.90M	273.90M	294.30M	303.90M	296.40M	329.20M
Selling & admin expenses	88.00M	95.90M	102.70M	107.00M	99.50M	117.60M
Research & development	16.30M	19.10M	17.10M	21.80M	15.80M	19.70M
Operating profit	127.60M	158.90M	174.50M	175.10M	181.10M	191.90M
Pretax profit	110.50M	157.00M	171.90M	161.50M	180.10M	180.10M
Tax	24.10M	30.20M	34.00M	33.30M	44.70M	32.20M
Net profit	89.80M	131.80M	140.00M	132.10M	138.80M	154.00M
Basic EPS	1	2	2	2	2	2
Diluted EPS	1.23	1.82	1.92	1.82	1.92	2.15

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	894.40M	1.06B	1.37B	1.74B	1.92B	1.94B	1.54B	1.98B
Cash & ST investments	337.40M	439.10M	615.50M	762.60M	894.30M	853.90M	484.60M	791.30M
Inventory	214.50M	235.70M	321.30M	378.40M	414.80M	434.70M	377.00M	443.90M
Total assets	1.98B	2.34B	2.79B	3.31B	3.62B	3.83B	3.64B	4.27B
Total current liabilities	283.70M	341.60M	503.40M	594.10M	519.00M	671.80M	550.40M	654.90M
Short-term debt	100.00K	11.90M	12.40M	53.50M	18.20M	151.70M	17.90M	22.70M
Long-term debt	196.00M	255.00M	252.90M	208.80M	206.70M	72.80M	202.60M	202.80M
Total liabilities	582,600,000.00	768,200,000.00	939,300,000.00	978,400,000.00	931,900,000.00	948,500,000.00	961,100,000.00	1,094,000,000.00
Total equity	1.40B	1.57B	1.85B	2.34B	2.68B	2.88B	2.68B	3.18B
Retained earnings	1.35B	1.55B	1.85B	2.46B	2.99B	3.52B	3.96B	4.37B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	1.46B	1.68B	1.82B	1.98B	1.83B	1.81B
Cash & ST investments	404.20M	509.70M	628.50M	791.30M	521.40M	435.80M
Inventory	388.70M	421.10M	438.00M	443.90M	452.60M	447.40M
Total assets	3.62B	3.95B	4.11B	4.27B	4.11B	4.08B
Total current liabilities	526.70M	604.60M	635.40M	654.90M	674.00M	640.50M
Short-term debt	21.80M	20.90M	21.40M	22.70M	21.40M	20.90M
Long-term debt	202.60M	202.60M	202.70M	202.80M	202.80M	202.90M
Total liabilities	935,100,000.00	1,023,700,000.00	1,054,300,000.00	1,094,000,000.00	1,119,400,000.00	1,086,200,000.00
Total equity	2.68B	2.93B	3.05B	3.18B	2.99B	2.99B
Retained earnings	4.03B	4.14B	4.26B	4.37B	4.48B	4.62B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	288.60M	367.20M	472.50M	584.00M	724.00M	776.50M	653.40M	754.80M
Depreciation & amortization	104.40M	103.40M	109.10M	122.30M	120.60M	137.30M	155.40M	171.40M
Free cash flow	183.90M	240.80M	298.10M	330.60M	439.40M	414.50M	276.40M	468.90M
Dividends paid	-42.10M	-45.10M	-48.10M	-51.10M	-54.10M	-57.00M	-59.10M	-61.20M
Stock buybacks / issuance	-70.80M	-85.30M	-121.40M	-151.90M	-222.20M	-451.20M	-566.60M	-136.80M
Ending cash balance	337.40M	439.10M	615.50M	762.60M	894.30M	853.90M	484.60M	791.30M

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	129.40M	177.10M	197.20M	251.10M	89.90M	124.00M
Depreciation & amortization	40.00M	41.40M	43.00M	47.00M	45.20M	46.20M
Free cash flow	58.10M	101.90M	133.90M	175.00M	47.20M	80.80M
Dividends paid	-15.20M	-15.10M	-15.10M	-15.80M	-15.80M	-15.70M
Stock buybacks / issuance	-136.00M	-500.00K	-100.00K	-200.00K	-300.10M	-156.70M
Ending cash balance	404.20M	509.70M	628.50M	791.30M	521.40M	435.80M

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	15.46	16.28	20.20	31.59	23.34	21.32	17.71	16.85
ROA %	10.77	11.19	13.48	21.67	16.91	15.94	13.19	12.48
ROIC %	13.82	14.05	17.23	27.60	20.77	18.66	15.52	14.82
5-year avg ROE %	12.95	13.48	15.59	19.22	21.37	22.55	22.83	22.16
EBIT margin %	14.50	16.32	19.07	26.74	23.82	23.97	20.34	19.56
FCF / sales %	10.71	13.09	13.89	11.68	15.22	14.05	9.55	15.25
Current ratio	3.15	3.10	2.73	2.93	3.70	2.88	2.79	3.02
Quick ratio	2.21	2.22	1.99	2.11	2.70	2.03	1.88	2.09
Debt / assets	9.91	14.06	11.66	9.82	8.79	8.07	8.30	7.52
LT debt / equity	14.04	20.18	16.89	11.64	11.16	5.46	10.60	9.40
Interest coverage	29.65	35.33	49.94	92.33	87.06	78.56	196.17	1,202.80
Revenue CAGR (3Y) %	7.05	6.83	10.32	18.14	16.20	11.17	0.72	2.12
Net income CAGR (3Y) %	29.35	18.95	31.95	47.34	34.33	19.68	-9.37	-5.55
FCF CAGR (3Y) %	31.54	69.78	31.03	21.59	22.20	11.61	-5.79	2.19

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	17.42	17.72	16.94	16.85	19.13	19.09
ROA %	12.94	13.11	12.64	12.48	14.05	14.07
ROIC %	15.22	15.51	14.92	14.82	16.83	16.95
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	19.70	20.18	20.02	19.56	20.88	20.98
FCF / sales %	10.60	11.62	12.56	15.25	14.22	13.13
Current ratio	2.77	2.78	2.87	3.02	2.71	2.82
Quick ratio	1.80	1.81	1.97	2.09	1.79	1.79
Debt / assets	8.38	7.67	7.25	7.52	7.69	7.66
LT debt / equity	10.49	9.64	9.05	9.40	9.86	9.74
Interest coverage	316.89	1,493.25	-6,042.00	1,202.80	336.25	155.13
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Single-engine

Proprietary products is the largest reported line at 82.84% of revenue, across 2 reported segments.
The next-largest line, West Vantage, is a distant second at 17.16% - a sharp slowdown here would have little to offset it.

Revenue breakdown most recent period

Business

Proprietary products82.84%

West Vantage17.16%

Quote time 2026-10-08 07:35:06 · For reference only, not investment advice and not tailored to your situation.